We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$8.68M 0.06%
4,589
-10,851
-70% -$22.4M
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$8.24M 0.05%
250,000
– –
HALO icon
53
Halozyme
HALO
$12.3B
$8.18M 0.05%
449,969
-833,960
-65% -$14.6M
MNTA
54
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$8.11M 0.05%
308,500
– –
VKTX icon
55
Viking Therapeutics
VKTX
$3.95B
$7.4M 0.05%
+425,000
New +$5.06M
FSTX
56
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$7.39M 0.05%
153,286
+60,000
+64% +$3.01M
AUTL
57
Autolus Therapeutics
AUTL
$641M
$7.22M 0.05%
235,294
– –
YARW
58
Yarrow Bioscience
YARW
$97.2M
$6.89M 0.05%
194
– –
SYRS
59
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.85M 0.05%
57,484
– –
GTHX
60
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.65M 0.04%
127,236
-42,256
-25% -$2.3M
IFRX icon
61
InflaRx
IFRX
$309M
$6.14M 0.04%
178,987
-79,837
-31% -$2.58M
ACHN
62
DELISTED
Achillion Pharmaceuticals
ACHN
$6.04M 0.04%
1,639,948
-303,672
-16% -$905K
ARWR icon
63
Arrowhead Research
ARWR
$12.3B
$5.89M 0.04%
+307,496
New +$5.05M
ASMB icon
64
Assembly Biosciences
ASMB
$700M
$5.52M 0.04%
12,382
– –
NTLA icon
65
Intellia Therapeutics
NTLA
$1.8B
$5.51M 0.04%
192,538
-354,384
-65% -$10.3M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$5.23M 0.03%
414,029
– –
GNMX
67
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.86M 0.03%
3,950,419
-104,723
-3% -$117K
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$4.8M 0.03%
83,900
-80,000
-49% -$3.93M
GLMD icon
69
Galmed Pharmaceuticals
GLMD
$4.48M
$4.4M 0.03%
225
-217
-49% -$4.06M
ALKS icon
70
Alkermes
ALKS
$8.11B
$4.25M 0.03%
100,251
– –
YMAB
71
DELISTED
Y-mAbs Therapeutics
YMAB
$3.98M 0.03%
+150,000
New +$3.81M
FOMX
72
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.94M 0.03%
688,075
-802,126
-54% -$4.59M
CRNX icon
73
Crinetics Pharmaceuticals
CRNX
$8.99B
$3.76M 0.02%
+131,250
New +$3.9M
FTSV
74
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.73M 0.02%
250,000
– –
APLS
75
DELISTED
Apellis Pharmaceuticals
APLS
$3.49M 0.02%
196,078
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2018 Portfolio in Review

As of Q3 2018, Julian Baker held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Julian Baker added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Julian Baker's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Julian Baker fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Julian Baker's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Julian Baker opened 12 new positions and closed 27 in Q3 2018.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.